XOMA Royalty Corporation

$26.62

$-1.37 (-4.89%)

Jan 5, 2026

Price History (1Y)

Analysis

XOMA Royalty Corporation is a biotechnology company listed in the healthcare sector with a market capitalization of $329.64 million and 13 employees. The company's financial health indicates a gross margin of 95.1%, an operating margin of -14.2%, and a profit margin of 45.9%. It generates returns on equity (ROE) and assets (ROA) of 22.5% and 1.4%, respectively, while maintaining a debt to equity ratio of 124.02. The company's balance sheet is supported by $46.71 million in cash and $133.89 million in debt. The company's valuation metrics show a price to earnings (P/E) ratio of 37.49 and forward P/E of 12.44, with revenue growth exceeding 29.9% year-over-year. The current ratio is 3.91.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About XOMA Royalty Corporation

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Visit website →

Key Statistics

Market Cap
$329.64M
P/E Ratio
37.49
52-Week High
$39.92
52-Week Low
$18.35
Avg Volume
102.91K
Beta
0.89

Company Info

Exchange
NGM
Country
United States
Employees
13